Preimplantation Genetic Testing Market Global Trends, Industry Size, Growth, Opportunities, and Forecast to 2031


Preimplantation genetic diagnosis (PGD) is performed among couples that have a higher risk of transmitting a genetic condition to their offspring. The technique is employed in in-vitro fertilization centers globally to select the euploid embryos to transfer and improve the clinical outcome of the clinical pregnancy, embryo implantation, and live birth rates. The ability to identify the preimplantation embryos with the genetic defects prior to the initiation of the pregnancy also offers an attractive alternative to chorionic villous sampling or amniocentesis.

The preimplantation genetic testing is set to grow at a significant rate in the upcoming years as the technology and awareness regarding the test improve.

The global preimplantation genetic testing market was valued at $972.1 million in 2020 and is expected to reach $2,725.7 million by 2031, registering a CAGR of 9.69% during the forecast period 2021-2031.

The growth is attributed to the advancing maternal age globally, rising adoption of in-vitro fertilization, increasing awareness of genetic testing, and rising emphasis on predictive testing. Further, continued significant investments by biotechnology firms to improve the technology for genetic testing and to improve affordability have also promoted the prominence of preimplantation genetic testing.

Market Segmentation 

 • Product Type – Reagents and Consumables, Kits and Services 

 • Application – Structural Chromosomal Abnormalities, Single Gene Disorder and Others 

 • Technology - Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH/FISH), Microarray 

 • End User – Diagnostic Center, Research Center, and Others 

 Regional Segmentation 

 • North America – U.S., Canada • Europe – France, Italy, U.K., Spain, Netherlands, Russia, and Rest-of-Europe • Asia-Pacific – China, Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific (RoAPAC) • Rest-of-the-World


Competitive Landscape

The exponential rise in the usage of in-vitro fertilization facilities as an option for healthy childbirth and increasing affordability for genetic testing on a global level has created awareness as well as demand among consumers, which has eventually led to the companies to invest in the development of more such preimplantation genetic test. The companies such as Agilent Technologies, Inc. and Natera, Inc. have been incorporating major strategies to enhance their market presence via key developments. The other major contributors to the market include companies such as Thermo Fisher Scientific, PerkinElmer, Inc., Invitae Inc., and Igenomix.

Based on region, North America holds the largest share of the preimplantation genetic testing market due to eased regulatory scenario and a large number of IVF facilities offering such PGT tests. Further, substantial investments made by biotechnology companies to improve the genetic testing facilities and advancing technologies along with the rise in per capita...

Do you already have an account? Log in here

Join the discussion


To read and post comments you need to login or register